Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 November 2021 | Story Andrè Damons
Prof Motlalepula Matsabisa
Good news galore. Prof Motlalepula Matsabisa, Professor and Director of Pharmacology at the University of the Free State (UFS), received more good news recently when he was awarded a Visiting Professorship at the Beijing University of Chinese Medicine (BUCM) in Beijing, China, as well as being elected as the Deputy President of the South African Society for Basic and Clinical Pharmacology. Prof Matsabisa was also recommended by Dr Blade Nzimande, Minister of Higher Education, Science and Technology, part of the IBSA technical committee.

Prof Motlalepula Matsabisa, Professor and Director of Pharmacology at the University of the Free State (UFS), received more good news recently when he was awarded a Visiting Professorship at the Beijing University of Chinese Medicine (BUCM) in Beijing, China. This news comes at the same time as the traditional medicine expert has been elected as the Deputy President of the South African Society for Basic and Clinical Pharmacology.

This is, however, not the end of the good news for Prof Matsabisa. Dr Blade Nzimande, Minister of Higher Education, Science and Technology, recommended him to Naledi Pandor, Minister of International Relations and Cooperation, to be part of the India, Brazil and South Africa (IBSA) working group in traditional medicine. As a member of the Department of Science and Innovation (DSI) Indigenous Knowledge-based Bio-Innovation programme, Prof Matsabisa, together with Prof Nceba Gqaleni, is part of the IBSA technical committee. Prof Matsabisa is also part of a technical team for National Department of Health on traditional medicines for the IBSA countries 

Unexpected honours

“I was not expecting any of these honours. It comes as a total shock. To have gone through the stringent evaluation and selection process at the BUCM and made it to the university’s highest award, is an honour. This is recognition of my academic and research quality by my peers on an international level.

“Being elected to lead a society of researchers and clinicians in the field of Pharmacology in the country is further recognition nationally of the academic and research excellence status. These awards coming at the same time is unbelievable. I am proud of the work I do as well as a gesture of support from scientists nationally and internationally and the support from UFS having allowed me to do what I do best academically,” says Prof Matsabisa.

According to him, some of the key expectations for this Visiting Professorship at the BUCM are teaching, to do collaborative research and conduct workshops jointly as well as joint leverage of research funding and co-publications. Prof Matsabisa will now, together with his counterparts at BUCM, discuss and synchronise their teaching and research so they plan the visit to benefit the UFS and the BUCM.

The South African Society for Basic and Clinical Pharmacology’s main activities are to bring pharmacologists together and share new scientific knowledge and developments in the field, explains Prof Matsabisa. The Society is for teaching and training; including research in both basic and clinical pharmacology, to support pharmacology conferences nationally and continentally. “We develop young pharmacologists and are also affiliated to international pharmacology societies. The purpose of the South African Society for Basic and Clinical Pharmacology is to excel and grow the pharmacology field in medicine.”

A good year for pharmacology and the UFS

This has been a good year for him and the team, for pharmacology and the UFS, says Prof Matsabisa. Most recently, Prof Matsabisa and the Department of Pharmacology received a grant of R58 million to establish one of the most advanced modern Pharmacology GLP-accredited research and development laboratories in the country, and possibly in the region. The department has also been awarded an annual Technology and Innovation Agency Platform (TIA) grant of R17 million for the next five years early this year.

“I am able to do what I do and achieve all this because of teamwork. I have a value chain of teams from support staff, cleaners, security, technical and research scientists with me. I have good students, postdoctoral fellows as well as management behind me.

“I hope such an environment can be given to all researchers to do what they do best and be supported fully and genuinely by senior management with decisions that are favourable to growing the institution without any favouritism or prejudice to anyone. It has indeed been a good year with all the funding we received. Watch this space for more.”

Looking forward most to China

Prof Matsabisa says he is looking forward to taking some of his postgraduate students with him to spend time at BUCM for training and conducting research. Says Prof Matsabisa: “I have very good postgraduate research students that need all the support. I look forward to spending a month or so at BUCM teaching BUCM students. I will leave my students there in good hands for 6-12 months per year. I promise, when these students return, they will return with a positive attitude for research and accountability.”

This was the case for him when he got a British scholarship to spend time at GlaxoSmithKline and the University of Bradford in the UK for his PhD. 

Prof Matsabisa hopes to use this Professorship at BUCM to popularise the work of the UFS and to create opportunities for new and upcoming researchers in the field of Pharmacology of Medicinal plants. This is his development plan

News Archive

Research eradicates bacteria from avocado facility
2017-01-17

 Description: Listeria monocytogenes Tags: Listeria monocytogenes

Listeria monocytogenes as seen under an electron
microscope. The photo was taken with a transmission
electron microscope at the microscopy unit of the UFS.
Bacteriophages (lollipop-like structures) can be seen
next to the bacterial cells.
Photo: Supplied

“The aim of my project was to identify and characterise the contamination problem in an avocado-processing facility and then to find a solution,” said Dr Amy Strydom, postdoctoral fellow in the Department of Microbial Biochemical and Food Biotechnology at the University of the Free State (UFS).

Her PhD, “Control of Listeria monocytogenes in an Avocado-processing Facility”, aimed to identify and characterise the contamination problem in a facility where avocados were processed into guacamole. Dr Strydom completed her MSc in food science in 2009 at Stellenbosch University and this was the catalyst for her starting her PhD in microbiology in 2012 at the UFS. The research was conducted over a period of four years and she graduated in 2016. The research project was funded by the National Research Foundation.

The opportunity to work closely with the food industry further motivated Dr Strydom to conduct her research. The research has made a significant contribution to a food producer (avocado facility) that will sell products that are not contaminated with any pathogens. The public will then buy food that is safe for human consumption.


What is Listeria monocytogenes?

Listeria monocytogenes is a food-borne pathogenic bacterium. When a food product is contaminated with L. monocytogenes, it will not be altered in ways that are obvious to the consumer, such as taste and smell. When ingested, however, it can cause a wide range of illnesses in people with impaired immune systems. “Risk groups include newborn babies, the elderly, and people suffering from diseases that weaken their immune systems,” Dr Strydom said. The processing adjustments based on her findings resulted in decreased numbers of Listeria in the facility.

The bacteria can also survive and grow at refrigeration temperatures, making them dangerous food pathogens, organisms which can cause illnesses [in humans]. Dr Strydom worked closely with the facility and developed an in-house monitoring system by means of which the facility could test their products and the processing environment. She also evaluated bacteriophages as a biological control agent in the processing facility. Bacteriophages are viruses that can only infect specific strains of bacteria. Despite bacteriophage products specifically intended for the use of controlling L. monocytogenes being commercially available in the food industry, Dr Strydom found that only 26% of the L. monocytogenes population in the facility was destroyed by the ListexP100TM product. “I concluded that the genetic diversity of the bacteria in the facility was too high and that the bacteriophages could not be used as a control measure. However, there is much we do not understand about bacteriophages, and with a few adjustments, we might be able to use them in the food industry.”

Microbiological and molecular characterisation of L. monocytogenes

The bacteria were isolated and purified using basic microbiological culturing. Characterisation was done based on specific genes present in the bacterial genome. “I amplified these genes with polymerase chain reaction (PCR), using various primers targeting these specific genes,” Dr Strydom said. Some amplification results were analysed with a subsequent restriction digestion where the genes were cut in specific areas with enzymes to create fragments. The lengths of these fragments can be used to differentiate between strains. “I also compared the whole genomes of some of the bacterial strains.” The bacteriophages were then isolated from waste water samples at the facility using the isolated bacterial strains. “However, I was not able to isolate a bacteriophage that could infect the bacteria in the facility.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept